Test an oncolytic virus treatment for solid tumors
Part of Cancer, Digestive system clinical trials.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor that cannot be removed or has come back/spread
- You’ve either already tried standard treatment and it stopped working, or there is no standard option for your cancer
- Your doctors can measure at least one tumor spot on scans to track response
- You feel well enough for treatment (ECOG 0–1) and are expected to live more than 3 months
- At least one tumor can be reached with an injection directly into the tumor
- You have adequate blood/organ function and can follow study instructions and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational injection (OH2) that goes directly into tumors. It may help shrink tumors and control cancer in people with certain advanced solid tumors who have run out of other options.
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new intravenous drug called IDOV-SAFE in people with advanced solid tumors that have stopped responding to standard treatments or have no effective standard option. The goal is to see if it is safe and effective.
This early-phase trial tests a cancer-killing virus (OTS-412) that is injected directly into tumors. It is for people with solid tumors that have not responded to standard treatments, including immunotherapy. The goal is to see if the virus can shrink or control the injected tumors.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.